ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus

Cecilia Chung, Gul Karakoc, Jorge Gamboa, Jonathan Mosley, Nancy Cox, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Drug toxicity, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white blood cell counts (leucopenia) affect approximately 50% of patients with systemic lupus erythematosus (SLE) and often correlates with active disease. A variant in the ACKR1 promoter region (rs2814778-C) that is associated with neutropenia of no clinical significance is common among populations of African (AA) but not European ancestry (EA). We examined the hypotheses that: 1) leucopenia is more frequent in AA than EA patients with SLE, and 2) that the ACKR1 genotype rs2814778-CC accounts for the higher frequency of leucopenia in AA patients.

Methods: We performed a retrospective cohort study at a tertiary care system in EA (n=574) and AA (n=190) patients with SLE who had genetic and electronic health record (EHR) data. Ancestry was defined by principal components (PCs) and HapMap reference. White blood cell (WBC) and platelet counts after the first diagnosis code for SLE were extracted; leucopenia was defined as a WBC count < 4,000 cells/mm3 and thrombocytopenia as a platelet count < 100,000 cells/mm3. Genotyping was performed using the Illumina Infinium® Expanded Multi-Ethnic Genotyping Array. The ACKR1 SNP — rs2814778 C/T—was directly genotyped. Only the CC genotype is associated with lower neutrophil counts; thus, patients with TT and TC genotypes were compared to those with CC genotype. We examined the association of CC genotype with platelet count as differences in WBC counts by genotype may be confounded by other SLE-related factors (e.g., disease activity or medications).

Results: The mean age at first diagnosis of SLE in the EHR was 42.3 (SD=16.6) years; patients were predominantly female (89%), and 25% were of AA. The median and lowest WBC counts were lower in AA than EA patients, and over a mean of 7.6 (5.6) years of follow-up, the rate of leucopenia was 60.0% in AA and 36.8% in EA patients (OR=2.6, 95%CI: 1.8-3.6, P=3.26E-08) (Table 1). The rs2814778-CC genotype was absent among EA patients but present in 70% of AA patients and was associated with lower WBC counts and more frequent leucopenia (OR=3.9, 95%CI: 1.7-8.9, P=0.001). The race differences observed in median WBC, lowest WBC, and rate of leucopenia were no longer significant after excluding AA individuals with the rs2814778-CC genotype (Table 1). Thrombocytopenia was more frequent in AA (22.1%) than EA (13.2%) patients, but in AA patients rs2814778-CC genotype was not associated with thrombocytopenia (CC 22.6% vs CT/TT 21.1%, P=0.870).

Conclusion: In SLE, AA patients had lower WBC counts and higher rates of leucopenia and thrombocytopenia than EA patients. The differences in WBC measures were largely explained by the rs2814778-CC genotype; this genotype could drive disparities in cytotoxic drug initiation and dose regulation and potentially influence outcomes in clinical practice.

Supporting image 1

Table 1


Disclosures: C. Chung, None; G. Karakoc, None; J. Gamboa, None; J. Mosley, None; N. Cox, None; M. Stein, None; V. Kawai, None.

To cite this abstract in AMA style:

Chung C, Karakoc G, Gamboa J, Mosley J, Cox N, Stein M, Kawai V. Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/ancestry-ackr1-and-leucopenia-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ancestry-ackr1-and-leucopenia-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology